A stock is considered overvalued if its price significantly exceeds the GF Value Line and undervalued if it falls substantially below. Date: Open Price: Close Price: Change: Bio-Rad Laboratories Stock Forecast for 2023: January 2023: 767: 773: 0.78.

Becton Dickinson and Company Bio-Rad Laboratories MegaCor Diagnostik GmbH. Bio-Rad Laboratories stock forecasts for 2023-2027. The clinical diagnostics unit, Bio-Rads revenue driver, through which it manufactures and sells blood and other diagnostic test kits to hospitals and physicians, reported sales of 368.1 million. The GF Value is a proprietary valuation model developed by GuruFocus, estimating the intrinsic value of a stock based on historical trading multiples, a company's past business growth, and future performance predictions. Forecast Report provides details analysis of Rapid Medical Diagnostic Device. Bio-Rads life science segment that serves biotech, pharmaceutical and food testing clients, reported a 17.1 fall in sales to 263.5 million. Warning! GuruFocus has detected 3 Warning Sign with BIO. The company owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier and operates globally with major markets in the Americas, Europe, Africa, and Asia-Pacific. Headquartered in Hercules, California, Bio-Rad Laboratories develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. With a market cap of $11.9 billion and sales amounting to $2.8 billion, Bio-Rad Laboratories' stock appears to be significantly undervalued based on the GF Value of $612.61. The PEAD projected a Neutral outlook for BIO after a Positive over reaction following its earnings release placing the stock in drift B with an expected. COVID-related sales were 2.6 million in the first quarter of 2023 versus approximately 45 million. On a currency-neutral basis, quarterly sales decreased 0.3 percent compared to the same period in 2022. Bio-Rad Laboratories is forecast to grow earnings and revenue by 57.6 and 3.7 per annum respectively while EPS is expected to grow by 57.5 per annum. As of July 23, 2023, Bio-Rad Laboratories Inc (NYSE:BIO) posted a gain of 4.01% with a closing price of $414.18. First-quarter 2023 net sales were 676.8 million, a decrease of 3.3 percent compared to 700.1 million reported for the first quarter of 2022. The average Bio Rad Laboratories stock price prediction forecasts a potential upside of 70.91 from the current BIO share price of 306.89.

Bio rad stock forecast